PT2831111T - Moléculas de ligação a ang2 - Google Patents

Moléculas de ligação a ang2

Info

Publication number
PT2831111T
PT2831111T PT13718796T PT13718796T PT2831111T PT 2831111 T PT2831111 T PT 2831111T PT 13718796 T PT13718796 T PT 13718796T PT 13718796 T PT13718796 T PT 13718796T PT 2831111 T PT2831111 T PT 2831111T
Authority
PT
Portugal
Prior art keywords
ang2
binding molecules
molecules
binding
Prior art date
Application number
PT13718796T
Other languages
English (en)
Portuguese (pt)
Inventor
Depla Erik
Buyse Marie-Ange
Gschwind Andreas
Georg Ott Rene
Borges Eric
Boucneau Joachim
Merchiers Pascal
Stevenaert Frederik
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2831111(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT2831111T publication Critical patent/PT2831111T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT13718796T 2012-03-30 2013-03-27 Moléculas de ligação a ang2 PT2831111T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12162615 2012-03-30

Publications (1)

Publication Number Publication Date
PT2831111T true PT2831111T (pt) 2019-05-31

Family

ID=48190468

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13718796T PT2831111T (pt) 2012-03-30 2013-03-27 Moléculas de ligação a ang2

Country Status (27)

Country Link
US (5) US20130259859A1 (en:Method)
EP (1) EP2831111B1 (en:Method)
JP (1) JP5970734B2 (en:Method)
KR (1) KR102020255B1 (en:Method)
CN (1) CN104321344B (en:Method)
AU (1) AU2013241769B2 (en:Method)
BR (1) BR112014023415B1 (en:Method)
CA (1) CA2865464C (en:Method)
CL (1) CL2014002393A1 (en:Method)
CY (1) CY1122007T1 (en:Method)
DK (1) DK2831111T3 (en:Method)
EA (1) EA031182B1 (en:Method)
ES (1) ES2729165T3 (en:Method)
HR (1) HRP20190817T1 (en:Method)
HU (1) HUE044263T2 (en:Method)
IL (1) IL234234B (en:Method)
IN (1) IN2014DN06904A (en:Method)
LT (1) LT2831111T (en:Method)
MX (1) MX350248B (en:Method)
NZ (1) NZ628584A (en:Method)
PH (1) PH12014502179B1 (en:Method)
PL (1) PL2831111T3 (en:Method)
PT (1) PT2831111T (en:Method)
RS (1) RS58732B1 (en:Method)
SI (1) SI2831111T1 (en:Method)
TR (1) TR201908638T4 (en:Method)
WO (1) WO2013144266A1 (en:Method)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
JP2017532342A (ja) 2014-10-17 2017-11-02 アムジエン・インコーポレーテツド 眼療法のためのアンジオポエチン−１及びアンジオポエチン−２を対象とする抗体
JP7064670B2 (ja) * 2015-03-31 2022-05-11 ソリッソ ファーマシューティカルズ，インク． プロテアーゼで切断可能なリンカーを有するペプチド構築体
DK3328886T3 (da) * 2015-07-29 2020-11-02 Allergan Inc Tungkæde antistoffer over for ang-2
CN110088136A (zh) * 2016-10-13 2019-08-02 达纳-法伯癌症研究所有限公司 使用基因表达签名预测黑素瘤中对于ctla4封锁的应答和耐药性的组合物和方法
KR102143132B1 (ko) * 2016-12-26 2020-08-10 기초과학연구원 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
MX2019014199A (es) * 2017-06-02 2020-01-23 Boehringer Ingelheim Int Tratamiento de combinacion antineoplasico.
CN108659130B (zh) * 2018-05-28 2021-09-10 长春力太生物技术有限公司 一种抗癌胚抗原纳米抗体及其应用
CN113056285B (zh) 2018-06-29 2025-02-07 璟尚生物制药公司 抗肿瘤免疫检查点调节剂拮抗剂
CN113728004A (zh) * 2019-02-25 2021-11-30 药物抗体公司 抗Ang2抗体及其用途
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
CN114340735B (zh) 2019-06-28 2024-11-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
KR20220148188A (ko) * 2020-03-03 2022-11-04 앱티튜드 메디칼 시스템즈, 아이엔씨. 압타머 및 이의 용도
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
US20240279324A1 (en) 2021-06-03 2024-08-22 Gensun Biopharma Inc. Multispecific antagonists
JP2024534964A (ja) * 2021-09-10 2024-09-26 ソーター・バイオファーマ・プライベイト・リミテッド 抗ａｎｇ２抗体、その調製方法及び使用
WO2024065268A1 (zh) 2022-09-28 2024-04-04 科兴生物制药股份有限公司 能够识别ang-2的抗体或抗原结合片段和同时识别vegf和ang-2的双抗
CN115819592A (zh) * 2022-12-27 2023-03-21 上海医药集团生物治疗技术有限公司 靶向ror1的抗原结合蛋白
WO2025117641A2 (en) * 2023-12-01 2025-06-05 Tavotek Biotherapeutics (Hong Kong) Limited ANTIBODIES TARGETING DISEASE ASSOCIATED ANTIGEN AND γδ T CELL RECEPTORS AND USES THEREOF
WO2025137089A1 (en) * 2023-12-19 2025-06-26 Beam Therapeutics Inc. Cd19-binding polypeptides, compositions comprising the same, and methods for use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AU2003283137B8 (en) 2002-11-08 2010-07-29 Ablynx N.V. Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
EP1814917A2 (en) 2004-10-13 2007-08-08 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
PL1838733T3 (pl) 2004-12-21 2012-02-29 Medimmune Ltd Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
MX2008015532A (es) 2006-06-06 2008-12-18 Genentech Inc Composiciones y metodos para la modulacion del desarrollo vascular.
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
WO2009109635A2 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
CN102112155B (zh) * 2008-06-05 2016-08-10 埃博灵克斯股份有限公司 针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽
WO2010066836A2 (en) * 2008-12-10 2010-06-17 Ablynx Nv Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2

Also Published As

Publication number Publication date
CN104321344B (zh) 2017-11-21
EP2831111A1 (en) 2015-02-04
PH12014502179A1 (en) 2014-12-10
LT2831111T (lt) 2019-05-10
BR112014023415A2 (pt) 2017-07-11
US20200207845A1 (en) 2020-07-02
US20130259859A1 (en) 2013-10-03
MX350248B (es) 2017-08-31
EA201401065A1 (ru) 2015-03-31
CN104321344A (zh) 2015-01-28
AU2013241769A1 (en) 2014-08-28
RS58732B1 (sr) 2019-06-28
KR102020255B1 (ko) 2019-09-10
US20170107281A1 (en) 2017-04-20
US20230203146A1 (en) 2023-06-29
IN2014DN06904A (en:Method) 2015-05-15
PL2831111T3 (pl) 2019-09-30
EP2831111B1 (en) 2019-03-20
HRP20190817T1 (hr) 2019-06-28
TR201908638T4 (tr) 2019-07-22
NZ628584A (en) 2016-04-29
CA2865464C (en) 2022-07-12
JP2015516805A (ja) 2015-06-18
SI2831111T1 (sl) 2019-06-28
BR112014023415B1 (pt) 2022-04-12
JP5970734B2 (ja) 2016-08-17
MX2014011171A (es) 2015-03-06
DK2831111T3 (en) 2019-04-29
ES2729165T3 (es) 2019-10-30
HUE044263T2 (hu) 2019-10-28
KR20140146606A (ko) 2014-12-26
CA2865464A1 (en) 2013-10-03
US20190135907A1 (en) 2019-05-09
PH12014502179B1 (en) 2014-12-10
CL2014002393A1 (es) 2015-01-23
AU2013241769B2 (en) 2017-05-11
WO2013144266A1 (en) 2013-10-03
EA031182B1 (ru) 2018-11-30
IL234234B (en) 2020-06-30
CY1122007T1 (el) 2020-10-14

Similar Documents

Publication Publication Date Title
IL234234B (en) 2ang binding molecules
DK3327112T3 (en) Agse-deficient stamme
DK2830816T3 (en) Hidtil ukendt coatingkoncept
AP2015008266A0 (en) 1L-18 binding molecules
EP2935220A4 (en) PERI-carbinol
GB2518803B (en) Headshaft
GB201203307D0 (en) Remvox
GB201205953D0 (en) SmartMat
GB201205681D0 (en) Catshield
GB201205515D0 (en) Shutterball
GB201205354D0 (en) Herbscan bookcradle
GB201205311D0 (en) InternalGCN
GB201205034D0 (en) Boozshooz
GB201204911D0 (en) Superswoosher
GB201204748D0 (en) Toretear
GB201204316D0 (en) Comniview
GB201204245D0 (en) MobiKey
GB201204164D0 (en) Plugstop
GB201204088D0 (en) Tidythatcable
GB201203962D0 (en) Locnlatch
GB201203776D0 (en) Sili-m8
GB201203777D0 (en) Quit-clip
GB201203815D0 (en) Mini-meals
GB201203808D0 (en) MicBooth
GB201203612D0 (en) Ishopfront